Anti-CD33 antibody

Anti-CD33 antibody

• DataSheet
• Material Safety Data Sheets (MSDS)

Rabbit Monoclonal to Human CD33

FCM

Human CD33 / Siglec-3

CD33 antibody; CD33 antibody; FLJ00391 antibody; gp67 antibody; Siglec-3 antibody; gp67 antibody; SIGLEC3 antibody; SIGLEC-3 antibody; P67 antibody

Rabbit IgG

This antibody was obtained from a rabbit immunized with purified, recombinant Human CD33 / Siglec-3 and conjugated with APC under optimum conditions, the unreacted APC was removed.

Monoclonal

Aqueous solution containing 0.5% BSA and 0.09% sodium azide

This antibody is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze !
Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.

FCM

Myeloid cell surface antigen CD33 also known as Sialic acid binding Ig-like lectin 3, CD33 antigen or Siglec-3, is a member of the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. This Single-pass type I membrane protein contains 1 Ig-like C2-type (immunoglobulin-like) domain and 1 Ig-like V-type (immunoglobulin-like) domain. CD33 /Siglec-3 is a putative adhesion molecule of myelomonocytic-derived cells that mediates sialic-acid dependent binding to cells. CD33 /Siglec-3 preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. CD33/Siglec-3 induces apoptosis in acute myeloid leukemia (in vitro). CD33/Siglec-3 can function as a sialic acid-dependent cell adhesion molecule and that binding can be modulated by endogenous sialoglycoconjugates when CD33 is expressed in a plasma membrane.

Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy